-
![Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders](/abs-image/US/2016/01/28/US20160024088A1/abs.jpg.150x150.jpg)
21.发明申请Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders 审中-公开新型吡啶并[1,2-a] Pryazine及其用于治疗神经退行性和神经性疾病公开(公告)号：US20160024088A1
公开(公告)日：2016-01-28
申请号：US14877118
申请日：2015-10-07
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Douglas Scott Johnson , Chakrapani Subramanyam , Christopher John O'Donnell , Christopher William am Ende , Michael Eric Green , Nandini Chaturbhai Patel , Cory Michael Stiff , Tuan Phong Tran , Gregory Wayne Kauffman , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中化合物具有说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
公开(公告)号：US08828401B2
公开(公告)日：2014-09-09
申请号：US13670612
申请日：2012-11-07
Applicant: Pfizer Inc.
Inventor： Matthew David Doroski , Andreas Maderna , Christopher John O'Donnell , Chakrapani Subramanyam , Beth Vetelino , Russell George Dushin , Pavel Strop , Edmund Idris Graziani
CPC classification number: C07K7/06 , A61K38/06 , A61K38/07 , A61K38/08 , A61K47/6803 , A61K47/6811 , A61K47/6851 , A61K47/6855 , A61K47/6863 , A61K47/6889 , C07K5/0205 , C07K5/0808 , C07K7/02 , C07K16/00 , C07K2319/30
Abstract: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
Abstract translation: 本发明涉及细胞毒性五肽，其抗体药物偶联物及其用于治疗癌症的方法。
-
公开(公告)号：US08822494B2
公开(公告)日：2014-09-02
申请号：US14072563
申请日：2013-11-05
Applicant: Pfizer Inc.
Inventor： Jennifer Elizabeth Davoren , Amy Beth Dounay , Ivan Viktorovich Efremov , David Lawrence Firman Gray , Scot Richard Mente , Steven Victor O'Neil , Bruce Nelsen Rogers , Chakrapani Subramanyam , Lei Zhang
IPC: C07D401/04 , C07D401/14 , A61K31/437
CPC classification number: C07D471/04 , A61K31/437 , C07D401/04 , C07D401/14 , C07D519/00
Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.
Abstract translation: 本发明部分提供式I化合物及其药学上可接受的盐和上述的N-氧化物; 制备过程; 中间体用于制备; 和含有这些化合物，盐或N-氧化物的组合物及其用于治疗D1介导的（或D1相关）疾病的用途，包括例如精神分裂症（例如，其认知和负面症状），认知障碍（例如，认知障碍相关 精神分裂症，AD，PD或药物治疗），ADHD，冲动，强迫性赌博，暴饮暴食，孤独症谱系障碍，MCI，年龄相关认知衰退，痴呆，RLS，帕金森病，亨廷顿舞蹈病，焦虑，抑郁，MDD，TRD 和双相情感障碍。
-
公开(公告)号：US11993625B2
公开(公告)日：2024-05-28
申请号：US16477290
申请日：2018-01-10
Applicant: PFIZER INC.
Inventor： Omar Khaled Ahmad , Stephen Paul Brown , Kenneth John Dirico , Russell Dushin , Gary Frederick Filzen , Sujiet Puthenveetil , Pavel Strop , Chakrapani Subramanyam , Lawrence N. Tumey
CPC classification number: C07H15/26 , A61K47/6807 , A61P35/00 , A61K45/06
Abstract: The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.
-
公开(公告)号：US11365263B2
公开(公告)日：2022-06-21
申请号：US17091097
申请日：2020-11-06
Applicant: PFIZER INC.
Inventor： Andreas Maderna , Chakrapani Subramanyam , Lawrence N. Tumey , Zecheng Chen , Jeffrey M. Casavant
IPC: C07K16/32 , C07D519/00 , C07F9/6561 , C07K5/062 , C07K5/09 , C07B59/00 , C07K16/28 , C07D495/04 , A61K47/68 , A61K47/65
Abstract: The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F1-L1-T-L2-F2 where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.
-
Patent Agency Ranking
公开(公告)号：US10723727B2
公开(公告)日：2020-07-28
申请号：US16072291
申请日：2017-01-27
Applicant: PFIZER INC. , CovX Technologies Ireland Limited
Inventor： Chakrapani Subramanyam , Lawrence N. Tumey , Longfei Xie , Carolyn Leverett , Beth C. Vetelino , Sai Chetan K. Sukuru , Sarah Hudson , Venkata Ramana Doppalapudi , Abhijit S. Bhat
IPC: A61K31/426 , A61K31/427 , A61K31/4025 , A61K47/65 , C07D277/56 , C07D417/12 , A61P35/00 , C07D277/42 , A61K47/68
Abstract: The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.
-
公开(公告)号：US09850232B2
公开(公告)日：2017-12-26
申请号：US15077229
申请日：2016-03-22
Applicant: PFIZER INC.
Inventor： David Lawrence Firman Gray , Lei Zhang , Michael Aaron Brodney , Michael Eric Green , Chakrapani Subramanyam
IPC: C07D403/12 , C07D471/04 , C07D401/12
CPC classification number: C07D403/12 , C07D401/12 , C07D471/04
Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
-
公开(公告)号：US09540352B2
公开(公告)日：2017-01-10
申请号：US14694333
申请日：2015-04-23
Applicant: PFIZER INC.
Inventor： David Lawrence Firman Gray , Lei Zhang , Michael Aaron Brodney , Michael Eric Green , Chakrapani Subramanyam
IPC: A61K31/4375 , C07D221/04 , C07D403/12 , C07D471/04 , C07D401/12
CPC classification number: C07D403/12 , C07D401/12 , C07D471/04
Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
Abstract translation: 本发明部分提供式I化合物及其药学上可接受的盐; 制备过程; 中间体用于制备; 和含有这些化合物或盐的组合物及其用于治疗D1介导的（或D1相关）疾病的用途，包括例如精神分裂症（例如其认知和阴性症状），分裂型人格障碍，认知障碍（例如，认知障碍相关 精神分裂症，AD，PD或药物治疗），ADHD，帕金森病，焦虑和抑郁。
-
公开(公告)号：US09527843B2
公开(公告)日：2016-12-27
申请号：US14819541
申请日：2015-08-06
Applicant: PFIZER INC.
Inventor： Jennifer Elizabeth Davoren , Amy Beth Dounay , Ivan Viktorovich Efremov , David Lawrence Firman Gray , Scot Richard Mente , Steven Victor O'Neil , Bruce Nelsen Rogers , Chakrapani Subramanyam , Lei Zhang
IPC: C07D401/14 , C07D401/04 , A61K31/437 , C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , A61K31/437 , C07D401/04 , C07D401/14 , C07D519/00
Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.
-
![Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders](/abs-image/US/2015/11/24/US09193726B2/abs.jpg.150x150.jpg)
30.发明授权Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders 有权取代的吡啶并[1,2-a]吡嗪用于治疗神经变性和神经障碍公开(公告)号：US09193726B2
公开(公告)日：2015-11-24
申请号：US14543020
申请日：2014-11-17
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Douglas Scott Johnson , Chakrapani Subramanyam , Christopher John O'Donnell , Christopher William am Ende , Michael Eric Green , Nandini Chaturbhai Patel , Cory Michael Stiff , Tuan Phong Tran , Gregory Wayne Kauffman , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: C07D241/36 , C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中化合物具有说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.029 seconds)
